Stammdaten
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Unternehmen & Branche
| Name | NexImmune, Inc. |
|---|---|
| Ticker | NEXI |
| CIK | 0001538210 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 139 USD |
| Beta | 5,47 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2024-06-30 | 10-Q | -2,326,765 | -1.69 | 5,861,300 | 696,350 | |
| 2024-03-31 | 10-Q | -3,077,273 | -2.46 | 8,990,613 | 2,742,573 | |
| 2023-12-31 | 10-K | -32,344,393 | -30.82 | 8,593,949 | 3,509,717 | |
| 2023-09-30 | 10-Q | -9,854,187 | -9.40 | 14,561,694 | 8,254,188 | |
| 2023-06-30 | 10-Q | -7,566,504 | -7.25 | 23,473,948 | 17,002,482 | |
| 2023-03-31 | 10-Q | -9,565,077 | -9.17 | 30,664,230 | 23,577,853 | |
| 2022-12-31 | 10-K | -62,506,199 | -64.95 | 43,059,824 | 32,300,484 | |
| 2022-09-30 | 10-Q | 0 | -14,729,380 | -15.09 | 57,674,448 | 47,715,533 |
| 2022-06-30 | 10-Q | 0 | -15,860,789 | -0.69 | 65,666,030 | 55,852,681 |
| 2022-03-31 | 10-Q | 0 | -15,023,005 | -0.66 | 78,313,954 | 70,393,179 |
| 2021-12-31 | 10-K | 0 | -50,901,508 | -2.54 | 91,032,116 | 83,760,667 |
| 2021-09-30 | 10-Q | 0 | -14,647,112 | -0.65 | 104,541,707 | 97,109,160 |
| 2021-06-30 | 10-Q | 0 | -12,182,247 | -0.54 | 115,392,641 | 109,909,420 |
| 2021-03-31 | 10-Q | 0 | -8,546,551 | -0.71 | 126,566,249 | 120,461,331 |
| 2020-12-31 | 10-K | 0 | -29,865,997 | -26.42 | 11,301,070 | -69,374,941 |
| 2020-09-30 | 10-Q | 0 | -8,608,735 | -7.52 | -62,855,162 | |
| 2020-06-30 | 10-Q | 0 | -6,930,525 | -54,562,092 | ||
| 2020-03-31 | 10-Q | -6,315,508 | -49,006,620 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.